Arrowhead Pharmaceuticals: The Fast-Follower Math Behind A $215 Million Voucher

Impact · against what's priced in

The news is modestly positive for Arrowhead due to strengthened liquidity and Phase III efficacy, but it creates a headwind for Ionis. Specifically, plozasiran's superior triglyceride reduction directly challenges the commercial upside the market is currently discounting for Ionis's Tryngolza.

IONS−0.30

Challenges what's priced in

The price assumes

The successful launch and commercial uptake of Tryngolza beyond initial prescriptions